Epiregulin Developer Kit Data Sheet Item 85-0366

Total Page：16

File Type：pdf, Size：1020Kb

Printed on: 02 Jan 2020, 02:44:41 pm; Printed by: MNGUYEN. Simoa® Epiregulin Developer Kit Data Sheet Item 85-0366 Description – Epiregulin (ER) Epiregulin is a 5.4 kDa protein and member of the epidermal growth factor (EGF) family. Epiregulin binds to ErbB proteins to regulate signaling in development, including the development of tumors. Epiregulin regulates inflammation, wound healing, tissue repair, and oocyte maturation through stimulus of angiogenesis, vascular remodeling, and cell proliferation. Calibration Curve: Calibrator concentrations and Lower Limit of Quantification are depicted in the figure below. This standard curve is for demonstration purposes; end users should prepare a standard curve for each assay run. LLOQ 5000 pg/mL 2500 pg/mL 625 pg/mL 500000 156 pg/mL 39.1 pg/mL IV Counts IV 50000 9.77 pg/mL 4.88 pg/mL 5000 hEpiregulin pg/mL Minimum Required Dilution (MRD) Endogenous Serum and Plasma Readings: Healthy EDTA plasma (n=4) and serum (n=4) samples were ! Diluted Sample volume 50 L measured. (1:2 Dilution)* per measurement *See Kit Instructions for details % Above LOD 100% % Above LLOQ 37.5% Assay Range: The upper end of the dynamic range is equal to the top calibrator concentration multiplied by MRD. Analytical 4.88 pg/mL LLOQ Note: Data described were developed during assay development. Functional 9.76 pg/mL Under different assay conditions, assay may perform differently LLOQ (x MRD) than shown. For complex matrices such as serum or plasma, assay diluent optimization (for example by adding blocking agents) may LOD 82.1 fg/mL improve performance of these matrices in this assay. Assay Range 0 – 10 ng/mL Quanterix Corporation ©2019 Quanterix, Inc. Simoa® and Quanterix® are registered trademarks of 900 Middlesex Turnpike, Billerica, MA 01821 Quanterix, Inc. For research use only. Not for use in diagnostic procedures. [email protected] DOC TEMPLATE-0117 02 DS-0389 01 Page 1 of 1.

Copy Link

Recommended publications

Table 2. Significant
Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
[Show full text]
Mesenchymal–Epithelial Interactions Involving Epiregulin in Tuberous Sclerosis Complex Hamartomas
Mesenchymal–epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas Shaowei Li*, Fumiko Takeuchi*, Ji-an Wang*, Qingyuan Fan*, Toshi Komurasaki†, Eric M. Billings‡, Gustavo Pacheco-Rodriguez‡, Joel Moss‡, and Thomas N. Darling*§ *Department of Dermatology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814-4712; †Molecular Biology Laboratory, Molecular and Pharmacology Laboratories, Taisho Pharmaceutical Co., Ltd., 430-1 Yoshino-cho, Saitma-shi, Saitama 331-9530, Japan; and ‡Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room 6D05, MSC 1590, Bethesda, MD 20892-1590 Communicated by Martha Vaughan, National Institutes of Health, Bethesda, MD, December 31, 2007 (received for review November 30, 2007) Patients with tuberous sclerosis complex (TSC) develop hamarto- Like other hamartomas, those in TSC skin contain abnormal mas containing biallelic inactivating mutations in either TSC1 or numbers of several types of cells. In the dermis, there are TSC2, resulting in mammalian target of rapamycin (mTOR) activa- increased numbers of large stellate fibroblasts, capillaries, and tion. Hamartomas overgrow epithelial and mesenchymal cells in dermal dendritic cells (6–9). The epidermis is acanthotic (i.e., TSC skin. The pathogenetic mechanisms for these changes had not thickened from increased numbers of keratinocytes in the spi- been investigated, and the existence or location of cells with nous layer). Acanthosis is pronounced in PFs and variable in AFs biallelic mutations (‘‘two-hit’’ cells) was unclear. We compared TSC (7, 8). The epidermis of treated AFs, several months after argon skin hamartomas (angioﬁbromas and periungual ﬁbromas) with or CO2 laser surgery, no longer appears acanthotic (10, 11).
[Show full text]
4 Transcription and Secretion Novel Regulator of Angiopoietin-Like Protein A
Acute-Phase Protein α1-Antitrypsin−−A Novel Regulator of Angiopoietin-like Protein 4 Transcription and Secretion This information is current as Eileen Frenzel, Sabine Wrenger, Stephan Immenschuh, of September 28, 2021. Rembert Koczulla, Ravi Mahadeva, H. Joachim Deeg, Charles A. Dinarello, Tobias Welte, A. Mario Q. Marcondes and Sabina Janciauskiene J Immunol 2014; 192:5354-5362; Prepublished online 23 April 2014; Downloaded from doi: 10.4049/jimmunol.1400378 http://www.jimmunol.org/content/192/11/5354 Supplementary http://www.jimmunol.org/content/suppl/2014/04/23/jimmunol.140037 http://www.jimmunol.org/ Material 8.DCSupplemental References This article cites 56 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/192/11/5354.full#ref-list-1 Why The JI? Submit online. by guest on September 28, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2014 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Acute-Phase Protein a1-Antitrypsin—A Novel Regulator of Angiopoietin-like Protein 4 Transcription and Secretion Eileen Frenzel,* Sabine Wrenger,* Stephan Immenschuh,† Rembert Koczulla,‡ Ravi Mahadeva,x H.
[Show full text]
Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Author Manuscript Published OnlineFirst on March 29, 2019; DOI: 10.1158/1535-7163.MCT-18-0582 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Functional analysis of somatic mutations affecting receptor tyrosine kinase family in metastatic colorectal cancer Leslie Duplaquet1, Martin Figeac2, Frédéric Leprêtre2, Charline Frandemiche3,4, Céline Villenet2, Shéhérazade Sebda2, Nasrin Sarafan-Vasseur5, Mélanie Bénozène1, Audrey Vinchent1, Gautier Goormachtigh1, Laurence Wicquart6, Nathalie Rousseau3, Ludivine Beaussire5, Stéphanie Truant7, Pierre Michel8, Jean-Christophe Sabourin9, Françoise Galateau-Sallé10, Marie-Christine Copin1,6, Gérard Zalcman11, Yvan De Launoit1, Véronique Fafeur1 and David Tulasne1 1 Univ. Lille, CNRS, Institut Pasteur de Lille, UMR 8161 - M3T – Mechanisms of Tumorigenesis and Target Therapies, F-59000 Lille, France. 2 Univ. Lille, Plateau de génomique fonctionnelle et structurale, CHU Lille, F-59000 Lille, France 3 TCBN - Tumorothèque Caen Basse-Normandie, F-14000 Caen, France. 4 Réseau Régional de Cancérologie – OncoBasseNormandie – F14000 Caen – France. 5 Normandie Univ, UNIROUEN, Inserm U1245, IRON group, Rouen University Hospital, Normandy Centre for Genomic and Personalized Medicine, F-76000 Rouen, France. 6 Tumorothèque du C2RC de Lille, F-59037 Lille, France. 7 Department of Digestive Surgery and Transplantation, CHU Lille, Univ Lille, 2 Avenue Oscar Lambret, 59037, Lille Cedex, France. 8 Department of hepato-gastroenterology, Rouen University Hospital, Normandie Univ, UNIROUEN, Inserm U1245, IRON group, F-76000 Rouen, France. 9 Department of Pathology, Normandy University, INSERM 1245, Rouen University Hospital, F 76 000 Rouen, France. 10 Department of Pathology, MESOPATH-MESOBANK, Centre León Bérard, Lyon, France. 11 Thoracic Oncology Department, CIC1425/CLIP2 Paris-Nord, Hôpital Bichat-Claude Bernard, Paris, France.
[Show full text]
HCC and Cancer Mutated Genes Summarized in the Literature Gene Symbol Gene Name References*
HCC and cancer mutated genes summarized in the literature Gene symbol Gene name References* A2M Alpha-2-macroglobulin (4) ABL1 c-abl oncogene 1, receptor tyrosine kinase (4,5,22) ACBD7 Acyl-Coenzyme A binding domain containing 7 (23) ACTL6A Actin-like 6A (4,5) ACTL6B Actin-like 6B (4) ACVR1B Activin A receptor, type IB (21,22) ACVR2A Activin A receptor, type IIA (4,21) ADAM10 ADAM metallopeptidase domain 10 (5) ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 (4) ADCY2 Adenylate cyclase 2 (brain) (26) AJUBA Ajuba LIM protein (21) AKAP9 A kinase (PRKA) anchor protein (yotiao) 9 (4) Akt AKT serine/threonine kinase (28) AKT1 v-akt murine thymoma viral oncogene homolog 1 (5,21,22) AKT2 v-akt murine thymoma viral oncogene homolog 2 (4) ALB Albumin (4) ALK Anaplastic lymphoma receptor tyrosine kinase (22) AMPH Amphiphysin (24) ANK3 Ankyrin 3, node of Ranvier (ankyrin G) (4) ANKRD12 Ankyrin repeat domain 12 (4) ANO1 Anoctamin 1, calcium activated chloride channel (4) APC Adenomatous polyposis coli (4,5,21,22,25,28) APOB Apolipoprotein B [including Ag(x) antigen] (4) AR Androgen receptor (5,21-23) ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 (4) ARHGAP35 Rho GTPase activating protein 35 (21) ARID1A AT rich interactive domain 1A (SWI-like) (4,5,21,22,24,25,27,28) ARID1B AT rich interactive domain 1B (SWI1-like) (4,5,22) ARID2 AT rich interactive domain 2 (ARID, RFX-like) (4,5,22,24,25,27,28) ARID4A AT rich interactive domain 4A (RBP1-like) (28) ARID5B AT rich interactive domain 5B (MRF1-like) (21) ASPM Asp (abnormal
[Show full text]
Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
[Show full text]
The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis
Published OnlineFirst September 8, 2009; DOI: 10.1158/0008-5472.CAN-09-0706 Molecular Biology, Pathobiology, and Genetics The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis Higinio Dopeso,1,5 Silvia Mateo-Lozano,1 Rocco Mazzolini,1 Paulo Rodrigues,1 Laura Lagares-Tena,1 Julian Ceron,2 Jordi Romero,1,5 Marielle Esteves,1 Stefania Landolfi,4 Javier Hernańdez-Losa,4 Julio Castanõ,3 Andrew J. Wilson,6 Santiago Ramon y Cajal,4 John M. Mariadason,7 Simo Schwartz, Jr.,3,5 and Diego Arango1,5 Groups of 1Molecular Oncology, 2Functional Genomics and Genetics, and 3Drug Delivery and Targeting, Molecular Biology and Biochemistry Research Center (CIBBIM-Nanomedicine) and 4Department of Pathology, Vall d’Hebron Hospital; 5CIBER de Bioingenierıá, Biomateriales y Nanomedicina, Barcelona, Spain; 6Department of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, Tennessee; and 7Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences, Austin Health, Heidelberg, Victoria, Australia Abstract Introduction Colorectal cancer is the second cause of cancer-related death Colorectal cancer is one of the leading causes of cancer-related in the western world, and although the genetic and molecular death in the western world and accounts for f1 million new mechanisms involved in the initiation and progression of these cases and f500,000 deaths every year worldwide. At the molecular tumors are among the best characterized, there are significant level, the constitutive activation of Wnt signaling is one of the gaps in our understanding of this disease. The role of EPHB hallmarks of colorectal cancer. Wnt activation most frequently signaling in colorectal cancer has only recently been realized.
[Show full text]
Genomic Signature of Parity in the Breast of Premenopausal Women
Santucci-Pereira et al. Breast Cancer Research (2019) 21:46 https://doi.org/10.1186/s13058-019-1128-x RESEARCH ARTICLE Open Access Genomic signature of parity in the breast of premenopausal women Julia Santucci-Pereira1*† , Anne Zeleniuch-Jacquotte2,3†, Yelena Afanasyeva2†, Hua Zhong2†, Michael Slifker4, Suraj Peri4, Eric A. Ross4, Ricardo López de Cicco1, Yubo Zhai1, Theresa Nguyen1, Fathima Sheriff1, Irma H. Russo1, Yanrong Su1, Alan A. Arslan2,5, Pal Bordas6,7, Per Lenner7, Janet Åhman6, Anna Stina Landström Eriksson6, Robert Johansson8, Göran Hallmans9, Paolo Toniolo5 and Jose Russo1 Abstract Background: Full-term pregnancy (FTP) at an early age confers long-term protection against breast cancer. Previously, we reported that a FTP imprints a specific gene expression profile in the breast of postmenopausal women. Herein, we evaluated gene expression changes induced by parity in the breast of premenopausal women. Methods: Gene expression profiling of normal breast tissue from 30 nulliparous (NP) and 79 parous (P) premenopausal volunteers was performed using Affymetrix microarrays. In addition to a discovery/validation analysis, we conducted an analysis of gene expression differences in P vs. NP women as a function of time since last FTP. Finally, a laser capture microdissection substudy was performed to compare the gene expression profile in the whole breast biopsy with that in the epithelial and stromal tissues. Results: Discovery/validation analysis identified 43 differentially expressed genes in P vs. NP breast. Analysis of expression as a function of time since FTP revealed 286 differentially expressed genes (238 up- and 48 downregulated) comparing all P vs. all NP, and/or P women whose last FTP was less than 5 years before biopsy vs.
[Show full text]
Crosstalk Between Granulocytes, Gut Microbes, Stem Cells, and the Bone Marrow Microenvironment
Crosstalk Between Granulocytes, Gut Microbes, Stem Cells, And The Bone Marrow Microenvironment by Emily Bowers A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Cell and Developmental Biology) in the University of Michigan 2018 Doctoral Committee: Professor Ivan Maillard, Chair Associate Professor Maria Ken Figueroa Assistant Professor Daniel Lucas-Alcaraz Paul de Kruif Endowed Professor Gabriel Nuñez Emily Bowers [email protected] ORCID ID: 0000-0003-1044-6690 © Emily Bowers 2018 ACKNOWLEDGEMENTS First, and foremost, I want to thank Daniel Lucas. You took the risk of taking me on as your first graduate student and for that, I am incredibly grateful. I have grown as a person and a scientist and owe so much of that to your guidance. You were there to push and support me every step of the way, you taught me to fight for my ideas and trust my instincts, to follow the science, and to never let anyone get in my way. To all the members of the Lucas lab, you have been there for me every step of the way. To Ana, we saw the lab grow from the relatively empty space it was in the beginning to the lab it blossomed into by the time we left. Your encouragement and endless support – and sleepless nights – for the many experiments we did directly aided in my success in graduate school. To Margot, you were always there for me to bounce ideas off of and were always at the ready to help out with experiments. You have been an incredible support system.
[Show full text]
A Novel Leptin Receptor Antagonist Uncouples Leptin's Metabolic And
Cellular and Molecular Life Sciences https://doi.org/10.1007/s00018-019-03004-9 Cellular andMolecular Life Sciences ORIGINAL ARTICLE A novel leptin receptor antagonist uncouples leptin’s metabolic and immune functions Lennart Zabeau1 · Joris Wauman1 · Julie Dam2 · Sandra Van Lint1 · Elianne Burg1 · Jennifer De Geest1 · Elke Rogge1 · Anisia Silva2 · Ralf Jockers2 · Jan Tavernier1 Received: 29 June 2018 / Revised: 28 December 2018 / Accepted: 2 January 2019 © The Author(s) 2019 Abstract Leptin links body energy stores to high energy demanding processes like reproduction and immunity. Based on leptin’s role in autoimmune diseases and cancer, several leptin and leptin receptor (LR) antagonists have been developed, but these intrinsically lead to unwanted weight gain. Here, we report on the uncoupling of leptin’s metabolic and immune functions based on the cross talk with the epidermal growth factor receptor (EGFR). We show that both receptors spontaneously interact and, remarkably, that this complex can partially overrule the lack of LR activation by a leptin antagonistic mutein. Moreover, this leptin mutant induces EGFR phosphorylation comparable to wild-type leptin. Exploiting this non-canonical leptin signalling pathway, we identifed a camelid single-domain antibody that selectively inhibits this LR-EGFR cross talk without interfering with homotypic LR signalling. Administration in vivo showed that this single-domain antibody did not interfere with leptin’s metabolic functions, but could reverse the leptin-driven protection against starvation-induced
[Show full text]
HB-EGF Improves the Hair Regenerative Potential of Adipose-Derived Stem Cells Via ROS Generation and Hck Phosphorylation
International Journal of Molecular Sciences Article HB-EGF Improves the Hair Regenerative Potential of Adipose-Derived Stem Cells via ROS Generation and Hck Phosphorylation Nahyun Choi 1,2, Won-Serk Kim 3, Sang Ho Oh 4 and Jong-Hyuk Sung 1,2,* 1 College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon 21983, Korea; [email protected] 2 STEMORE Co. Ltd., Incheon 21983, Korea 3 Department of Dermatology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Korea; [email protected] 4 Department of Dermatology, Severance Hospital and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul 03722, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-32-749-4506 Received: 25 November 2019; Accepted: 18 December 2019; Published: 23 December 2019 Abstract: Although adipose-derived stem cells (ASCs) have hair regenerative potential, their hair inductive capabilities are limited. The mitogenic and hair inductive eﬀects of heparin binding-epidermal growth factor-like growth factor (HB-EGF) on ASCs were investigated in this study and the underlying mechanism of stimulation was examined. Cell growth, migration, and self-renewal assays, as well as quantitative polymerase chain reactions and immunostaining, were carried out. Telogen-to-anagen transition and organ culture using vibrissa follicles were also conducted. HB-EGF signiﬁcantly increased ASC motility, including cell proliferation, migration, and self-renewal activity. The preconditioning of ASCs with HB-EGF induced telogen-to-anagen transition more rapidly in vivo, and injected PKH26-ASCs survived for longer periods of time. Conditioned medium obtained from HB-EGF-treated ASCs promoted hair growth in vivo, upregulating growth factors.
[Show full text]
Genetically Engineered Fusion Proteins for Treatment of Cancer
CANCER GENOMICS & PROTEOMICS 9: 357-372 (2012) Review Genetically Engineered Fusion Proteins for Treatment of Cancer ULRICH H. WEIDLE, BRITTA SCHNEIDER, GUY GEORGES and ULRICH BRINKMANN Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany Abstract. In this review, we summarize approaches to treat generated by combining entities derived from the ECDs of cancer with genetically engineered fusion proteins. Such two, or theoretically more, plasma membrane-associated proteins can act as decoy receptors for several ligands or as receptors. The fusion proteins, as outlined, can bind several recruiters of immune effector cells to tumor. Examples of ligands dedicated to one or several receptors inhibiting, interference with growth factor-mediated tumor growth and processes such as tumor-associated angiogenesis or human tumor-related angiogenesis with fusion proteins consisting of epidermal growth factor receptor (HER)-based signaling. the extracellular domains, and in some cases also of entities Another approach is the recruitment of immune effector cells of one or several receptors and the Fc part of human IgG1, to the tumor with genetically engineered fusion proteins. We are discussed. In addition, we present strategies for discuss fusion proteins of tumor-related antibodies and recruitment of immune effector cells to tumor with fusion cytokines or MHC-class I peptide complexes, T-cell receptor proteins. This can be achieved with fusion proteins consisting (TCR) cytokine fusion proteins, and fusions proteins of a of a tumor-related antibody and a cytokine or major T-cell-recruiting antibody and a tumor-cell receptor ligand or histocompatibilty complex class-I-peptide complexes, by a defined TCR.
[Show full text]